Linger Liu
Overview
Explore the profile of Linger Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
296
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu L, Chen B, Tang M, Guo Y, Hou J, Zhou W, et al.
Anticancer Drugs
. 2024 May;
35(8):752-756.
PMID: 38728054
Up to 80% of biliary tract cancer (BTC) patients relapse within 3 years after surgery and the efficacy of second-line treatment remains dismal for patients who progressed on gemcitabine and...
2.
HER2-positive advanced biliary tract cancer responds to second-line pyrotinib therapy: a case report
Liu L, Chen Y, Zhu X, Zhao L, Chen B
Anticancer Drugs
. 2023 Dec;
35(3):298-301.
PMID: 38037743
Biliary tract cancers are solid tumors with poor prognosis and over 70% of patients present in advanced stages. The efficacy of second-line treatment for patients who progressed on GC chemotherapy...
3.
Cai X, Gu D, Chen M, Liu L, Chen D, Lu L, et al.
Int J Med Sci
. 2018 Dec;
15(14):1640-1647.
PMID: 30588187
Colorectal cancer is one of the most common cancers and the leading cause of cancer-related death worldwide. The impact of the primary tumor location on the prognosis of patients with...
4.
Liu L, Fei Z, Chen M, Zhao L, Su H, Gu D, et al.
Radiat Oncol
. 2018 Aug;
13(1):148.
PMID: 30103765
Background: In the era of intensity-modulated radiotherapy (IMRT), the role of additional concurrent chemotherapy (CC) to radiotherapy (RT) after induction chemotherapy (IC) compared to IC followed by RT alone remains...
5.
Jin X, Chen Y, Chen H, Fei S, Chen D, Cai X, et al.
Clin Cancer Res
. 2017 Jun;
23(17):5311-5319.
PMID: 28606918
To identify tumor-derived exosomal biomarkers that are able to discriminate between adenocarcinoma and squamous cell carcinoma (SCC) as a noninvasive method in the early diagnosis of non-small cell lung cancer...